Form 4: Labcorp CEO Adam Schechter Sells 6,189 Shares Under 10b5-1 Plan

Labcorp's CEO, Adam Schechter, sold 6,189 shares of common stock at $243.47 per share on November 11, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Adam Schechter, the President and CEO of Labcorp Holdings Inc., sold 6,189 shares of common stock on November 11, 2024.
• The sale was executed at a price of $243.47 per share.
• This transaction was conducted under a pre-arranged trading plan that complies with Rule 10b5-1 of the Securities Exchange Act of 1934.
• Following the transaction, Mr. Schechter directly owns 87,441 shares of Labcorp common stock.
• The company, previously known as Laboratory Corporation of America Holdings (LCAH), reorganized into a new holding company structure on May 17, 2024, becoming Labcorp Holdings Inc. (LHI).

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by the CEO under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

Executive stock sales are a common occurrence and are often part of pre-arranged trading plans to avoid accusations of insider trading. This transaction is not unusual for a company of Labcorp's size and profile.

Comparison to Industry Standards

• Executive stock sales are a common practice across the industry, with many executives using 10b5-1 plans to manage their personal finances and avoid potential conflicts of interest.
• Companies like Quest Diagnostics (DGX) and other large healthcare providers also see similar transactions from their executives.
• The volume of shares sold by Mr. Schechter is not unusual for a CEO of a company with a market capitalization similar to Labcorp.

Stakeholder Impact

• The stock sale by the CEO may have a minor impact on shareholder sentiment, but it is unlikely to significantly affect the company's operations or long-term prospects.

Key Dates

Keywords

Labcorp, Adam Schechter, insider trading, stock sale, 10b5-1 plan, executive transaction, share sale